PRNewsWire
06 Aug 2026, 17:52 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The FDA stated that the HOPE-3 study for Deramiocel did not meet its pre-specified primary and secondary efficacy endpoints. — Failure to meet primary endpoints in a pivotal Phase 3 trial drastically reduces the likelihood of regulatory approval for the lead product candidate.
-0.90The FDA revealed that Capricor made modifications to its statistical analysis plan (SAP) without prior agency agreement prior to resubmitting its BLA. — Unauthorized changes to data analysis plans suggest data manipulation or 'p-hacking' to achieve significance, severely damaging company credibility.
-0.70A securities fraud class action lawsuit has been filed against Capricor alleging materially false and misleading statements regarding clinical trial data. — Litigation creates additional financial liability and reflects poor corporate governance, though it is a lagging indicator of the clinical failure.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company is facing a securities fraud class action lawsuit following a 64% stock collapse and FDA reports of unmet clinical trial endpoints.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
1h ago
